: To differentiate oncocytoma and chromophobe renal cell carcinoma (RCC) using radiomics features computed from spherical samples of image regions of interest, "radiomic biopsies" (RBs). : In a retrospective cohort study of 102 CT cases [68 males (67%), 34 females (33%); mean age ± SD, ], we pathology-confirmed 42 oncocytomas (41%) and 60 chromophobes (59%). A board-certified radiologist performed two RB rounds. From each RB round, we computed radiomics features and compared the performance of a random forest and AdaBoost binary classifier trained from the features. To control for overfitting, we performed 10 rounds of 70% to 30% train-test splits with feature-selection, cross-validation, and hyperparameter-optimization on each split. We evaluated the performance with test ROC AUC. We tested models on data from the other RB round and compared with the same round testing with the DeLong test. We clustered important features for each round and measured a bootstrapped adjusted Rand index agreement. : Our best classifiers achieved an average AUC of . We found no evidence of an effect for RB round ( ). We also found no evidence for a decrease in model performance when tested on the other RB round ( ). Feature clustering produced seven clusters in each RB round with high agreement ( , ). : A consistent radiomic signature can be derived from RBs and could help distinguish oncocytoma and chromophobe RCC.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423237PMC
http://dx.doi.org/10.1117/1.JMI.8.5.054501DOI Listing

Publication Analysis

Top Keywords

oncocytoma chromophobe
12
differentiate oncocytoma
8
chromophobe renal
8
renal cell
8
cell carcinoma
8
radiomics features
8
performed rounds
8
round
7
features
5
quantitative image
4

Similar Publications

Renal cell carcinoma is an aggressive form of kidney cancer, contributing to an estimated 138,000 deaths globally in 2017. Traditional treatments like chemotherapy and radiation are generally considered ineffective. Additionally, CD47 has been identified as a crucial tumor antigen involved in the development and progression of various cancers, including renal cell carcinoma.

View Article and Find Full Text PDF

Primary intrarenal hemangioma - A series of 39 cases.

Ann Diagn Pathol

January 2025

Department of Pathology and Laboratory Medicine, Brigham and Women's Hospital, Boston, USA. Electronic address:

Intrarenal hemangiomas lack concise clinicopathologic information, due to the predominance of single case reports and inclusion of other vascular neoplasms and hemangiomas of perirenal, hilar, and renal vein origin. Herein, in this multi-institutional study we evaluate clinicopathologic features of 39 intrarenal hemangiomas. The median age was 62 years (range = 27-94 years; 2:1 male to female ratio), with left-sided predominance (left = 21, right = 13; one case was bilateral).

View Article and Find Full Text PDF

RO and ChRCC are kidney tumours with overlapping characteristics, making differentiation between them challenging. The objective of this research is to create a radiogenomics map by correlating radiomic features to molecular phenotypes in ChRCC and RO, using resection as the gold standard. Fourteen patients (6 RO and 8 ChRCC) were included in the prospective study.

View Article and Find Full Text PDF
Article Synopsis
  • Renal Cell Carcinoma (RCC) is a prevalent type of cancer, and this study focused on examining the relationship between galectin-3 expression and various clinical factors in RCC patients.
  • A total of 71 patient samples were analyzed for galectin-3 levels through immunohistochemistry, revealing that most patients were male and the majority had clear cell carcinoma.
  • The findings suggested that while there was a significant difference in galectin-3 expression between genders, other factors like age and tumor characteristics showed no significant associations, indicating the complexity of galectin's role and the need for more extensive research.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!